A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Bendamustine vs. Bendamustine Alone in Patients With Relapsed Chronic Lymphocytic Leukemia

Trial Profile

A Phase 1b/2 Open Label Study to Evaluate the Safety and Efficacy of TRU-016 in Combination With Bendamustine vs. Bendamustine Alone in Patients With Relapsed Chronic Lymphocytic Leukemia

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Bendamustine (Primary) ; Otlertuzumab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Emergent BioSolutions; Emergent Product Development Seattle
  • Most Recent Events

    • 16 Dec 2016 Primary endpoint has been met. (Overall response rate (ORR)), as reported by an Aptevo Therapeutics media release.
    • 16 Dec 2016 The results from Phase II portion were published in the British Journal of Haematology (BJH) 2016, as reported by an Aptevo Therapeutics media release.
    • 16 Dec 2016 Results from Phase II portion published in an Aptevo Therapeutics Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top